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Abstract: Prolonged exposure to psychiatric pharmacological agents is often associated with marked
gastrointestinal phenomena, including changes in food intake, bowel motility, gastric emptying,
and transit time. Those changes are reflected in the gut microbiota composition of the patient and
can, therefore, be objectively measured. This is in contrast to the standard psychiatric evaluation of
patients, which includes symptoms that are subjectively assessed (i.e., mood, anxiety level, perception,
thought disorders, etc.). The association between a drug’s effect on the microbiota and psychiatric
symptoms may allow for quantifiable surrogate markers of treatment effectiveness. Changes in the
levels of specific drug-sensitive bacterial species can, thus, potentially serve as biomarkers for the
intake and effectiveness of psychiatric drugs. Here, we show substantial microbiota changes that
were associated with oxytocin administration and the decreased anxiety/depression-like behaviors
it conferred in a rat model of corticosterone-induced stress. Compared with oxytocin, citalopram
produced more minor effects on the rats’ microbiota. Alterations in the gut microbiota may, therefore,
reflect the consumption and effectiveness of some psychiatric drugs.
Keywords: microbiome; oxytocin; biomarker; psychiatry; gut-brain axis
1. Introduction
Humans are colonized by bacteria, fungi, archaea, and viruses, which are collectively
referred to as the microbiome. Most of the microbiome resides in the gut and may easily
be investigated via stool sampling and subsequent metagenomic DNA sequencing. Pro-
longed exposure to psychiatric pharmacological agents is often associated with marked
gastrointestinal phenomena, including changes in food intake, bowel motility, gastric emp-
tying, and transit time [1–3]. Unlike the relatively objective measurement of the microbiota
composition, accurate assessment of patients’ therapy adherence and treatment outcomes
represent a challenge in psychiatric medical care [4]. This is partly because, for most
psychopharmacological agents, compliance and response to treatments are subjectively
assessed based on self-reporting and physicians’ evaluations [5,6]. An interesting alter-
native is having changes in the psychiatric patients’ gut microbiota composition serve as
a measurable proxy for monitoring patients’ compliance and the therapeutic effects of
some drugs.
It is yet unclear how behavioral changes and drug intake affect the microbiota; how-
ever, mounting evidence suggests that physical and mental disturbances may lead to
changes in gastrointestinal (GI) motility [7,8] in both animals and humans [9–11]. Indeed,
in humans, anger, fear, pain, and anxiety, as well as intensive exercise, results in changes in
GI activity [8]. In rats, chronic stress results in initial delayed gastric emptying followed by
acceleration later on [12]. Medication intake [13,14] and changes in stool consistency, gas-
tric transit, and emptying time [15,16] also have a great impact on microbial composition.
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Previous microbiota studies have already shown a connection between the microbiota and
behavior, with the association of relative abundance of specific bacteria to stress exposure
and anxiety [17–21]. However, the association of microbial changes with additional factors
such as diet [22,23] and physical activity [24] limits the current use of the microbiota as a
biomarker. Nevertheless, an increasing amount of evidence suggests that the ‘gut brain
axis’ has a significant role to play in stress response [25–27]. This is especially evident by
the high sensitivity of the microbiota to the effect of stress [28–30] and by studies demon-
strating a correlative link of the microbiota composition with stress in both rodents [31–34]
and humans [35–37].
The degree of change in the microbiota composition between time points is sometimes
defined as volatility [38,39]. A recent study has concluded that gut microbial volatility is
influenced by stress since mice with a greater stress response exhibited a greater microbial
volatility. Furthermore, microbial volatility was positively correlated with cortisol and
corticosterone after chronic stress in humans and mice, respectively [40]. Another study
conducted on patients diagnosed with depression and anxiety showed that volatility was
different among patients and was affected by the type of drug used in their treatment [41].
Based on these recent studies, it is reasonable to propose that a large microbial volatility or
changes in specific taxa could sometimes indicate that certain psychiatric drugs have had
a physiological effect. To test whether microbiota can serve as a biomarker for treatment
success, we investigated the degree of microbiota composition change in response to drug
administration, as well as the correlation to behavioral parameters. We defined the degree
of fecal microbiota change as microbiota composition shift and tested it as a possible biomarker
predicting drug intake and success. Three agents known to elicit behavioral changes in rats
were investigated for their effects on the rats’ stool microbiota. These included corticos-
terone, an anxiogenic agent [42]; citalopram, a well-tolerated antidepressant and anxiolytic
agent of the SSRI (selective serotonin reuptake inhibitor) family [43–45], previously shown
to influence gut motility [46]; and oxytocin, a naturally produced neuropeptide and a
potential anxiolytic-like agent [47].
2. Materials and Methods
All animal experiments were conducted at the Faculty of Pharmacy of Belgrade and
were approved by the Committee for ‘Ethical Animal Care and Use’ of the Faculty of
Pharmacy University of Belgrade (Permit Number: 323-07-00067/2015-05), which acts in
accordance with the NIH Guide for the Care and Use of Laboratory Animals, 1996.
2.1. Animal Housing and Samples Collection
Eight-week-old male Wistar rats (Military Farm, Belgrade, Serbia) weighing 250–300 g
were housed in groups at a constant temperature of 20 ± 2 ◦C in a 12-h light/dark cycle,
with ad libitum access to water and commercial rat food. The bedding was changed three
times per week. After a 4-day adaptation period, the rats were randomly divided into
the experimental groups described in Figure 1. Fecal samples were collected from each
cage on day 1 and day 20 of the experiment. Gloves and sterile tweezers were used for the
collection of the samples. After each sampling, 70% ethanol was used for the re-sterilization
of tweezers. Upon collection, samples were placed in sterile Eppendorf tubes (2 mL) and
stored at −20 ◦C.
2.1.1. Multidrug Environment: Experimental Setup—Experiment 1
Seventy rats were randomly assigned to experimental groups, as detailed in Figure 1.
Stress was induced by chronic administration of corticosterone (Sigma-Aldrich Co., Cat.
No. C2505, St. Louis, MO, USA), dissolved in tap water containing 2% polyoxyethylene
glycol sorbitan monooleate (Tween 80®) to a final concentration of 100 mg/L for 21 days [42].
Non-invasive drinking water-mediated corticosterone administration was used to ensure
continual exposure to the elevated hormone level [48]. Citalopram HCL, 10 mg/kg BW,
oxytocin at 10 IU per animal, or pure saline were freshly dissolved in 400 uL saline and
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given on day 7 to 21 by subcutaneous administration injected at the same time every day
(9:00–10:00 AM). The control group received drinking water containing 2% Tween 80® for
21 days.
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2.1.2. Single Drug Environment: Experimental Setup—Experiment 2
Thirteen rats, individually housed, were randomly assigned into two experimental
groups, oxytocin-treated (six rats) and oxytocin-free (seven rats), as detailed in (Figure 1).
Drug administration and sample collections were according to the setup of Experiment 1.
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2.2. DNA Extraction and Microbiota Analysis
Total DNA from the fecal samples were extracted using the ‘PowerSoil DNA isolation
kit (MOBIO))’ according to the manufacturer’s protocol. PCR amplification of the bacterial
16 S rRNA gene was carried out with universal prokaryotic primers (containing 5’-end com-
mon sequences and their adaptors) (CS1-341F 5’-ACACTGACGACATGGTTCTACANNN
NCCTACGGGAGGCAGCAG and CS2-806R 5′-TACGGTAGCAGAGACTTGGTCTGGAC
TACHVGGGTWTCTAAT). Reactions were prepared in a dedicated PCR cabinet with a
filtered air laminar flow, using the Kappa2G DNA polymerase and the following PCR
conditions: 3 min in 95 ◦C, 25 cycles of 15 s in 95 ◦C, 15 s in 53 ◦C, and 15 s in 72 ◦C.
Negative controls containing no template were included to verify lack of contamina-
tion. Paired-end DNA sequencing was performed on the Illumina MiSeq platform at the
Chicago Sequencing Centre of the University of Illinois. Sequencing depth ranged from
12,335 to 26,603 seqs/sample for Experiment 1, and 1237 to 46,999 seqs/sample for Experi-
ment 2. To ensure data evenness, the data were rarefied to the depth of the lowest sample.
Initial merging of paired end reads and quality filtering was performed according
to the human microbiome project guidelines (http://www.hmpdacc.org/, accessed on
12 September 2019). Sequences were then analyzed using the Quantitative Insights Into
Microbial Ecology (QIIME) package [49]. Usearch 6.1 [50] was used for chimera detection
and removal; OTU picking (0.99 similarity) and taxonomy assignment were conducted
using the UCLUST algorithm and Greengenes 13.8.2013 database version as a reference.
Further identification of bacterial species was performed using the NCBI BLAST [51]
algorithm. Abundance weighted and unweighted UniFrac distance matrices, obtained
from QIIME, were exported to PAST [52], a statistical analysis program in which principle
coordinate analysis (PCoA) and analysis of similarity (ANOSIM) were performed. LDA
effect size estimation (LEfSe [53]) was applied to identify which bacterial taxa contribute
most to the differences between the two groups. The statistical significance threshold was
α = 0.05 for all tests.
2.3. Behavioral Data
Behavioral data were collected only in Experiment 1 (see below) using both the
elevated plus maze test (EPM), in which anxiety-like behavior is expressed by the animal
spending more time in the mazes’ enclosed arms), and the open field test (OF), in which
anxiety-like behavior is expressed by a decrease in rat locomotor activity and preference for
field edges. While behavioral tests were conducted per individual rat, the microbiota data
were collected per cage. Therefore, to compare these two variables, the mean behavioral
test score per cage was used.
3. Results
3.1. Oxytocin Has a Strong Impact on the Composition of Rat Fecal Microbiota
We used a previously established rat model for chemically induced stress [54] to
explore the influences of stress induction and anxiolytic modulation on the rats’ gut
microbiota in a multidrug environment.
Rats were divided into treatment groups as described in Figure 1. In brief, 12 cages
(housing 3–4 rats each) were continuously stress-induced by corticosterone for 21 days. The
anxiolytic/anti-depressive drug citalopram, oxytocin, a hormone with anxiolytic-like prop-
erties, or both were administered by daily injections between day 7 and 21. To control for
the injection effect, three cages received an injection of saline only. An additional nine cages
were kept stress-free (no corticosterone was administered) but received anxiolytic/control
injections (either oxytocin, citalopram, or saline). Fecal samples were taken for microbiota
analysis pre- and post-treatment (see Materials and Methods).
To better understand the effect each treatment had on the microbiota composition in a
multidrug environment, samples were analyzed by 16 S rRNA gene amplicon sequencing
and grouped by individual treatment. To overcome the overlap in the treatment groups,
the analysis was repeated three times, each employing a different grouping variable (i.e.,
Microorganisms 2021, 9, 1938 5 of 14
citalopram, oxytocin, or corticosterone status). Consequently, groups with a minimum of
nine samples were obtained, with a single common treatment differentiating them from
the rest of the samples. The pre- and post-treatment effect of the degree of clustering was
observable when the unweighted UniFrac distance matrix was visualized using PCoA
for corticosterone (ANOSIM, p = 0.003, R = 0.23) and more so for oxytocin (ANOSIM,
p = 0.001, R = 0.54), but not for citalopram (Supplementary Figure S1A–C). Pairwise
before/after unweighted UniFrac distances between samples were computed to assess
which treatment had the largest effect on the microbiota, i.e., led to the largest change in
microbial composition between experimental phase I (pre-treatment) and phase II (post-
treatment). Both oxytocin treatment and corticosterone stress induction caused significant
changes in bacterial composition (Kruskal–Wallis Test; corticosterone, p = 0.023; oxytocin,
p = 0.047). No such change was observed with citalopram (Figure 2A). Similar trends
were observed when abundance weighted UniFrac distances were used, but in this case,
the results did not reach statistical significance (Supplementary Figure S2). The degree of
change in the rats’ fecal microbiota pre- and post-treatment was thereafter defined as the
‘microbiota composition shift.’
The effects of different treatments were also evident when the entire phase II (post-
treatment) unweighted UniFrac distance matrix was visualized using PCoA. The separation
between oxytocin-treated and untreated animals was strong and statistically significant
(Figure 2B; ANOSIM, p = 0.001, R = 0.6). Corticosterone induced a lesser yet significant effect
on the microbiota (Supplementary Figure S3A; ANOSIM, p = 0.001, R = 0.43). No significant
effect was observed when cages were grouped according to citalopram (Supplementary
Figure S3B). To summarize, oxytocin seems to strongly affect the rat fecal microbiota in
both stressed and non-stressed animals.
A second experiment was performed in order to validate oxytocin’s effects as a single
drug. Thirteen individually housed rats were divided into treatment groups, as described
in (Figure 1). In brief, oxytocin or saline was administered by daily injections between day
7 and Day 21. Fecal samples were taken for microbiota analysis pre- and post-treatment
(see Materials and Methods). The ANOSIM results for the unweighted UniFrac analysis
were consistent with the first experiment, thereby showing that oxytocin treatment has
a strong and significant effect on the rats’ microbiota. This was evident when testing
the degree of clustering according to the experimental phase (pre- and post-treatment)
in the oxytocin-treated group (Figure 3A; ANOSIM, p = 0.002, R = 0.63), as well as when
comparing the degree of clustering according to treatment (oxytocin or saline) in all phase
II samples (Figure 3B; ANOSIM, p = 0.003, R = 0.44).
3.2. Changes in Relative Abundance of Specific Bacterial Taxa
We next attempted to identify which specific bacterial taxa drove the shift in microbial
composition between oxytocin-treated and untreated animals. To this end, the widely
used, LDA-based LEfSe [53] algorithm was applied. Seventeen taxa in the first experiment
and 12 in the second were identified as significantly contributing to the microbial shift
between oxytocin-treated and oxytocin-free samples. Four bacterial genera were consis-
tently identified across both independent experiments. Of those, Clostridium, Collinsella,
and Eubacterium tended to increase over time in all treatment groups. However, only in
the oxytocin-treated group was that increase strong and statistically significant (Figure 4A,
Supplementary Figure S4A,B). The genus Mogibacterium proved to be the most interesting
since it increased solely following oxytocin treatment, while its relative abundance in the
other treatment groups decreased over time (Figure 4B).
3.3. Specific Bacteria Are Associated with Changes in Behavior
Since oxytocin alone had a significant, directional, and consistent impact on the mi-
crobiota composition, samples from oxytocin-treated rats were chosen for analyzing the
possible link between that treatment, microbiota changes, and rat behavior. For compar-
isons with the microbiota, we used the cage mean behavioral test scores. The microbiota
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composition shift (pairwise-weighted UniFrac distances pre- and post-treatment) was
strongly and significantly associated with the change in behavioral tests scores mediated
by oxytocin (Spearman’s ρ for EPM Test parameters: ‘% of Open Time,’ r = 0.92, p = 0.001;
‘% of Open Entries,’ r = 0.92, p = 0.001; ‘Number of Total Entries,’ r = 0.75, p = 0.03; ‘Closed
Arm-Entries,’ r = 0.6, p = 0.09; Figure 5A) (Spearman’s ρ for OF Test parameters: ‘% of Time
in the Central Zone,’ r = 0.7, p = 0.04; ‘% of Distance in the Central Zone,’ r = 0.7, p = 0.04;
‘Distance’ (m), r = 0.7, p = 0.03; Figure 5B).
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Figure 3. Oxytocin effect in a single-treatment validation experiment. Each point represents the
microbiota composition of a single rat: (A) samples from the oxytocin-treated group only; pre-
treatment (green) vs. post-treatment (red) ANOSIM, p = 0.002, R = 0.63; (B) all post-treatment
samples, oxytocin-treated (red) or saline-treated (green) ANOSIM, p = 0.003, R = 0.44.
To further test the possible association of rats’ behavior with specific bacterial taxa,
we used the ‘percentage of time spent in open space’ and the ‘percentage of time spent
in the central zone’ from the EPM and OF tests, respectively. Using LEfSe, the micro-
biota composition of “low-anxiety rats” (eight samples taken from cages scoring the mean
highest scores) was compared with “high anxiety rats” (eight samples taken from cages
scoring the mean lowest scores). Additionally, comparisons for pre- and post-treatment
samples were performed. Only bacterial taxa presenting similar and statistically significant
associations with behavior in both analyses were further analyzed. The discriminating
taxa identified by LEfSe were then directly correlated to the behavioral test scores (cage
means). With EPM test scores, the abundance of Adlercreutzia (previously linked to de-
pression in humans [55], and to anxiety and consumption of antidepressant medication
in rodents [56–58]) and of Turicibacter (previously linked to depressive-like behavior in
rats [59]) were significantly associated to increased anxiety-like behavior levels (Spearman’s
ρ ‘% of Open Time’: Adlercreutzia, p = 0.002, r = -0.62; Turicibacter, p = 0.004, r = −0.6). In
contrast, Mogibacterium and Eubacterium abundance was associated with decreased levels
of anxiety-like behavior (Spearman’s ρ ‘% of Open Time’: Mogibacterium, p = 0.01, r = 0.53;
Eubacterium, p = 0.03, r = 0.46). After FDR correction, the p-values were 0.008, 0.008, 0.013,
and 0.03 for Adlercreutzia, Turicibacter, Mogibacterium, and Eubacterium, respectively. No sta-
tistically significant associations could be found when using the OF test scores, potentially
because, in these tests, the effect size was smaller than in the EPM.
Mogibacterium’s relative abundance represented the best biomarker for oxytocin effec-
tiveness, as it was significantly and positively associated with both “low-anxiety” behavior
and oxytocin administration. Rats treated with oxytocin that then went on to display more
“low-anxiety” behaviors in the EPM test also had relatively higher levels of Mogibacterium
relative abundance (Spearman’s ρ for EPM Test parameters: ‘% of Open Time,’ r = 0.92,
p = 0.001; ‘% of Open Entries,’ r = 0.92, p = 0.0008; ‘Number of Total Entries,’ r = 0.84,
p = 0.006; ‘Closed Arm-Entries,’ r = 0.7, p = 0.06; Figure 5C).
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Eubacterium, p = 0.03, r = 0.46). After FDR correction, the p-values were 0.008, 0.008, 0.013, 
and 0.03 for Adlercreutzia, Turicibacter, Mogibacterium, and Eubacterium, respectively. No 
statistically significant associations could be found when using the OF test scores, poten-
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Figure 5. Correlation of behavioral test scores with microbiota parameters in oxytocin-treated rats. The cage mean behavioral
tests score was used. Spearman’s correlation values: (A) weighted UniFrac Distance and EPM test, p = 0.001, R = 0.92;
(B) weighted UniFrac Distance and OF test, p = 0.04, R = 0.7; (C) relative abundance of Mogibacterium and EPM, p = 0.001,
R = 0.92.
4. Discussion
Precision, patient-adjusted therapy is critically neede in psychiatric m dicine since
drug responses can differ across individuals because of different pharmacokinetic and
pharmacodynamics parameters across patients [60]. However, our current understanding
of psychiatric diseases and drug mechanisms is generally too limited to achieve patient-
specific therapy. In order for treatments to become more individualized, objective physi-
ological parameters that assess the effectiveness of medication are needed. Microbiome
studies offer an opportunity to find such parameters for some psychiatric drugs, as objec-
tive changes in the microbiota may reflect treatment efficacy [61]. The problem, however, is
that microbiota are very sensitive to pe turbati ns and are influ nced by a wid variety of
factors. For exampl , patients taking several classes of medica ions or with mood swings
affecting their activity levels (such as depressed vs. anic in bipolar disorder) may experi-
ence changes in their microbiota as a result. These confounding factors compromise the
use of the fecal microbiota features as biomarkers in psychiatry.
Nonetheless, this study aimed to be a proof of concept for the use of microbiota
changes as indicators for drug intake. Using a multidrug environment with stress appli-
cation in a rat model, we modeled some aspects of the psychiatric field environment. We
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observed that the microbiota composition shift and the relative abundance of the genus
Mogibacterium were drug-specific changes in the microbiota. These changes were specifi-
cally induced by oxytocin and consistently associated with rat behavior, regardless of other
drugs given or whether stress was applied.
Even though oxytocin is known to have a role in social bonding, sexual reproduction,
and childbirth [62], today, it is medically used mostly for the augmentation of vaginal
delivery [63]. However, as it is a profound anxiolytic and anti-stress factor in the brain [47],
the use of oxytocin as an anxiolytic in preclinical and clinical research, though highly
debated, points to the oxytocinergic system as a target for novel anxiolytics [64]. Oxytocin’s
effect on human behavior was portrayed as relatively weak and inconsistent, suggesting
its influence on behavior might be situation- or individual-dependent [65], but it was pre-
sumed that imbalance of the endogenous brain oxytocinergic system underlies the etiology
of anxiety disorders, particularly those with a social component [47]. There is also conflict-
ing evidence of oxytocin’s influence on the gut, especially gut motility. Oxytocin-treated
rats, for example, previously showed either an increase [66] or a decrease [67,68] in bowel
movement and emptying. This inconsistency could be partly due to the diverse effects of
different responses in different parts of the GI tract, as oxytocin’s receptors are expressed
across the entire GI tract in humans [69] and in rats [66,67,70]. In regard to the microbiota,
although mouse studies have shown that the gut microbiota can influence oxytocin in the
brain [71,72], there is little data on how exogenous oxytocin affects the microbiota.
Nevertheless, under oxytocin treatment, we observed a strong shift in the microbiota
composition manifesting as a large UniFrac distance between pre- and post-treatment
states that we referred to as a ‘microbiota composition shift.’ The magnitude of that shift
was also positively associated with the rat’s anxiolytic-like scores in behavioral tests. Thus,
we were able to define a parameter that may reflect the administration and effectiveness
of oxytocin treatment in rats. Furthermore, we were able to pinpoint a specific bacterial
genus, Mogibacterium, which showed an increase in relative abundance following oxytocin
treatment and was associated with low-anxiety behavior in rats. This demonstrated that
specific members of the microbiota can be associated with drug efficacy and not just drug
intake and raises the hope that such biomarkers could be identified in the future in the
human microbiome.
Our study also had several limitations. First, the study was performed on adult male
rats, and while behavioral tests were conducted per individual animal, the microbiota data
were collected per cage for Experiment 1. Therefore, to compare these two variables, the
mean behavioral test score per cage was used, reducing sensitivity. Second, it should be
acknowledged that, unlike oxytocin, citalopram did not produce a substantial shift in the
microbiota, indicating that for some drugs, the correspondence between changes to the
microbiota and efficacy may be low. Third, 16 S rRNA gene amplicon sequencing reveals
taxonomy only, and one is limited in the ability to draw conclusions on functional changes
in the microbiota, for example, the ability to produce bioactive metabolites that may affect
host behavior or physiology. Future work should include shotgun metagenomics and
metabolomics in order to have not just better chances of identification of microbiota-based
indicators of treatment success but also to gain clues into the mechanism. Additionally,
the effects on immunity should also be explored, as often microbiota shifts can change
the levels of inflammation, which in turn can affect behavior. Fourth, rodent models are
a useful starting point, but because animals are nearly identical in their genotype and
environmental exposures, such studies cannot capture the large inter-individual variation
in humans, which makes the identification of broadly applicable clinical biomarkers a
challenging task.
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in corticosterone-induced chronic stress model: Focus on adrenal gland function. Psychoneuroendocrinology 2017, 80, 137–146.
[CrossRef] [PubMed]
55. Chung, Y.-C.E.; Chen, H.-C.; Chou, H.-C.L.; Chen, I.-M.; Lee, M.-S.; Chuang, L.-C.; Liu, Y.-W.; Lu, M.-L.; Chen, C.-H.; Wu, C.-S.;
et al. Exploration of microbiota targets for major depressive disorder and mood related traits. J. Psychiatr. Res. 2019, 111, 74–82.
[CrossRef] [PubMed]
56. Zhao, J.; Li, G.; Lu, W.; Huang, S.; Zhang, Z. Dominant and Subordinate Relationship Formed by Repeated Social Encounters
Alters Gut Microbiota in Greater Long-Tailed Hamsters. Microb. Ecol. 2019, 79, 998–1010. [CrossRef] [PubMed]
57. Lukic, I.; Getselter, D.; Ziv, O.; Oron, O.; Reuveni, E.; Koren, O.; Elliott, E. Antidepressants affect gut microbiota and Ruminococcus
flavefaciens is able to abolish their effects on depressive-like behavior. Transl. Psychiatry 2019, 9, 1–16. [CrossRef] [PubMed]
58. Xie, R.; Jiang, P.; Lin, L.; Jiang, J.; Yu, B.; Rao, J.; Liu, H.; Wei, W.; Qiao, Y. Oral treatment with Lactobacillus reuteri attenuates
depressive-like behaviors and serotonin metabolism alterations induced by chronic social defeat stress. J. Psychiatr. Res. 2020, 122,
70–78. [CrossRef] [PubMed]
59. Kelly, J.; Borre, Y.; Brien, C.O.; Patterson, E.; El Aidy, S.; Deane, J.; Kennedy, P.J.; Beers, S.; Scott, K.; Moloney, G.; et al. Transferring
the blues: Depression-associated gut microbiota induces neurobehavioural changes in the rat. J. Psychiatr. Res. 2016, 82, 109–118.
[CrossRef]
60. Gray, M. Geodiversity: Valuing and conserving abiotic nature. Wiley Publ. 2013, 17, 5324. [CrossRef]
61. Kashyap, P.C.; Chia, N.; Nelson, H.; Segal, E.; Elinav, E. Microbiome at the Frontier of Personalized Medicine. Mayo Clin. Proc.
2017, 92, 1855–1864. [CrossRef]
62. Carter, C.S. Oxytocin Pathways and the Evolution of Human Behavior. Annu. Rev. Psychol. 2014, 65, 17–39. [CrossRef]
63. Wei, S.-Q.; Luo, Z.-C.; Xu, H.; Fraser, W.D. The Effect of Early Oxytocin Augmentation in Labor. Obstet. Gynecol. 2009, 114,
641–649. [CrossRef]
64. Naja, W.J.; Aoun, M.P. Oxytocin and Anxiety Disorders: Translational and Therapeutic Aspects. Curr. Psychiatry Rep. 2017, 19, 67.
[CrossRef] [PubMed]
65. Bartz, J.A.; Zaki, J.; Bolger, N.; Ochsner, K.N. Social effects of oxytocin in humans: Context and person matter. Trends Cogn. Sci.
2011, 15, 301–309. [CrossRef] [PubMed]
66. Qin, J.; Feng, M.; Wang, C.; Ye, Y.; Wang, P.S.; Liu, C. Oxytocin receptor expressed on the smooth muscle mediates the excitatory
effect of oxytocin on gastric motility in rats. Neurogastroenterol. Motil. 2009, 21, 430–438. [CrossRef] [PubMed]
Microorganisms 2021, 9, 1938 14 of 14
67. Yang, X.; Xi, T.-F.; Li, Y.-X.; Wang, H.-H.; Qin, Y.; Zhang, J.-P.; Cai, W.-T.; Huang, M.-T.; Shen, J.-Q.; Fan, X.-M.; et al. Oxytocin
decreases colonic motility of cold water stressed ratsviaoxytocin receptors. World J. Gastroenterol. 2014, 20, 10886–10894. [CrossRef]
68. Wu, C.-L.; Doong, M.-L.; Wang, P.S. Involvement of cholecystokinin receptor in the inhibition of gastrointestinal motility by
oxytocin in ovariectomized rats. Eur. J. Pharmacol. 2008, 580, 407–415. [CrossRef] [PubMed]
69. Ohlsson, B.; Truedsson, M.; Djerf, P.; Sundler, F. Oxytocin is expressed throughout the human gastrointestinal tract. Regul. Pept.
2006, 135, 7–11. [CrossRef]
70. Welch, M.G.; Tamir, H.; Gross, K.J.; Chen, J.; Anwar, M.; Gershon, M.D. Expression and developmental regulation of oxytocin
(OT) and oxytocin receptors (OTR) in the enteric nervous system (ENS) and intestinal epithelium. J. Comp. Neurol. 2009, 512,
256–270. [CrossRef]
71. Desbonnet, L.; Clarke, G.; Traplin, A.; O’Sullivan, O.; Crispie, F.; Moloney, R.D.; Cotter, P.; Dinan, T.; Cryan, J. Gut microbiota
depletion from early adolescence in mice: Implications for brain and behaviour. Brain Behav. Immun. 2015, 48, 165–173. [CrossRef]
[PubMed]
72. Buffington, S.A.; Di Prisco, G.V.; Auchtung, T.A.; Ajami, N.J.; Petrosino, J.F.; Costa-Mattioli, M. Microbial Reconstitution Reverses
Maternal Diet-Induced Social and Synaptic Deficits in Offspring. Cell 2016, 165, 1762–1775. [CrossRef] [PubMed]
